Expression of CD133 in neuroendocrine neoplasms of the digestive tract: A detailed immunohistochemical analysis

Tohoku Journal of Experimental Medicine

Volumn 229, Issue 4, 2013, Pages 301-309

  Mia Jan, Khalilullah ^a   Munkhdelger, Jijgee ^a   Lee, Mi Ra ^a   Ji, Sun Young ^a   Kang, Tae Young ^a   Choi, Eunhee ^a   Cho, Mee Yon ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Cancer stem cells; CD133; Gastroenteropancreatic neuroendocrine tumors; Immunohistochemistry

Indexed keywords

CD133 ANTIGEN; CHROMOGRANIN A; SYNAPTOPHYSIN;

ADULT; AGED; ANTIGEN EXPRESSION; APPENDIX TUMOR; ARTICLE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; COLON TUMOR; CONTROLLED STUDY; DUODENUM TUMOR; FEMALE; GALLBLADDER TUMOR; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEUM TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; PROGNOSIS; RECTUM TUMOR; SMALL INTESTINE TUMOR; STOMACH TUMOR; TUMOR LOCALIZATION;

ANTIGENS, CD; DIGESTIVE SYSTEM NEOPLASMS; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASTIC STEM CELLS; NEUROENDOCRINE TUMORS; PEPTIDES; REPUBLIC OF KOREA; TUMOR MARKERS, BIOLOGICAL;

EID: 84877811394     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.229.301     Document Type: Article

References (37)

1. Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D. & Rich, J.N.(2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-760.
2. Cho, M.Y., Kim, J.M., Sohn, J.H., Kim, M.J., Kim, K.M., Kim, W.H., Kim, H., Kook, M.C., Park do, Y., Lee, J.H., Chang, H., Jung, E.S., Kim, H.K., Jin, S.Y., Choi, J.H., Gu, M.J., Kim, S., Kang, M.S., Cho, C.H., Park, M.I., Kang, Y.K., Kim, Y.W., Yoon, S.O., Bae, H.I., Joo, M., Moon, W.S., Kang, D.Y. & Chang, S.J.(2012) Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors(GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res. Treat., 44, 157-165.
3. Corbeil, D., Röper, K., Hellwig, A., Tavian, M., Miraglia, S., Watt, S.M., Simmons, P.J., Peault, B., Buck, D.W. & Huttner, W.B.(2000) The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J. Biol. Chem., 275, 5512-5520.
4. Corbeil, D., Marzesco, A.M., Wilsch-Brauninger, M. & Huttner, W.B.(2010) The intriguing links between prominin-1(CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and(neuro) epithelial cell differentiation. FEBS Lett., 584, 1659-1664.
5. Cui, F., Wang, J., Chen, D. & Chen, Y.J.(2011) CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol. Rep., 25, 701-708.
6. Edge, S.B. & Compton, C.C.(2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol., 17, 1471-1474.
7. Fan, L., He, F., Liu, H., Zhu, J., Liu, Y., Yin, Z., Wang, L., Guo, Y., Wang, Z., Yan, Q. & Huang, G.(2011) CD133: a potential indicator for differentiation and prognosis of human cholan-giocarcinoma. BMC Cancer, 11, 320.
8. Gaur, P., Sceusi, E.L., Samuel, S., Xia, L., Fan, F., Zhou, Y., Lu, J., Tozzi, F., Lopez-Berestein, G., Vivas-Mejia, P., Rashid, A., Fleming, J.B., Abdalla, E.K., Curley, S.A., Vauthey, J.N., Sood, A.K., Yao, J.C. & Ellis, L.M.(2011) Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology, 141, 1728-1737.
9. Giebel, B., Corbeil, D., Beckmann, J., Höhn, J., Freund, D., Giesen, K., Fischer, J., Kögler, G. & Wernet, P.(2004) Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood, 104, 2332-2338.
10. Hambardzumyan, D., Becher, O.J. & Holland, E.C.(2008) Cancer stem cells and survival pathways. Cell Cycle, 7, 1371-1378.
11. Immervoll, H., Hoem, D., Sakariassen, P.O., Steffensen, O.J. & Molven, A.(2008) Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer, 8, 48.
12. Jao, S.W., Chen, S.F., Lin, Y.S., Chang, Y.C., Lee, T.Y., Wu, C.C., Jin, J.S. & Nieh, S.(2012) Cytoplasmic CD133 Expression is a Reliable Prognostic Indicator of Tumor Regression After Neoadjuvant Concurrent Chemoradiotherapy in Patients with Rectal Cancer. Ann. Surg. Oncol., 19, 3432-3440.
13. Klimstra, D.S., Modlin, I.R., Coppola, D., Lloyd, R.V. & Suster, S.(2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas, 39, 707-712.
14. Kojima, M., Ishii, G., Atsumi, N., Fujii, S., Saito, N. & Ochiai, A.(2008) Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci., 99, 1578-1583.
15. Krishnamurthy, P., Ross, D.D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K.E., Sarkadi, B., Sorrentino, B.P. & Schuetz, J.D.(2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem., 279, 24218-24225.
16. Kubo, T., Takigawa, N., Osawa, M., Harada, D., Ninomiya, T., Ochi, N., Ichihara, E., Yamane, H., Tanimoto, M. & Kiura, K.(2013) Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer science, 104, 78-84.
17. Lardon, J., Corbeil, D., Huttner, W.B., Ling, Z. & Bouwens, L.(2008) Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas. Pancreas, 36, e1-e6.
18. Lathia, J.D., Hitomi, M., Gallagher, J., Gadani, S.P., Adkins, J., Vasanji, A., Liu, L., Eyler, C.E., Heddleston, J.M., Wu, Q., Minhas, S., Soeda, A., Hoeppner, D.J., Ravin, R., McKay, R.D., McLendon, R.E., Corbeil, D., Chenn, A., Hjelmeland, A.B., Park, D.M. & Rich, J.N.(2011) Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis., 2, e200.
19. Miraglia, S., Godfrey, W., Yin, A.H., Atkins, K., Warnke, R., Holden, J.T., Warne, R., Holden J.T., Bray, R.A., Waller, E.K. & Buck, D.W.(1997) A novel five-transmembrane hemato-poietic stem cell antigen: isolation, characterization, and molecular cloning. Blood, 90, 5013-5021.
20. Modlin, I.M., Lye, K.D. & Kidd, M.(2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97, 934-959.
21. Modlin, I.M., Kidd, M., Latich, I., Zikusoka, M.N. & Shapiro, M.D.(2005) Current status of gastrointestinal carcinoids. Gastroenterology, 128, 1717-1751.
22. Modlin, I.M., Oberg, K., Chung, D.C., Jensen, R.T., de Herder, W.W., Thakker, R.V., Caplin, M., Delle Fave, G., Kaltsas, G.A., Krenning, E.P., Moss, S.F., Nilsson, O., Rindi, G., Salazar, R., Ruszniewski, P. & Sundin, A.(2008) Gastroenter-opancreatic neuroendocrine tumours. Lancet Oncol., 9, 61-72.
23. Oberg, K. & Eriksson, B,(2005) Endocrine tumours of the pancreas. Best Pract. Res. Clin. Gastroenterol., 19, 753-781.
24. Pardal, R., Clarke, M.F. & Morrison, S.J.(2003) Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer, 3, 895-902.
25. Piyathilake, C.J., Frost, A.R., Manne, U., Weiss, H., Bell, W.C., Heimburger, D.C. & Grizzle, W.E.(2002) Differential expression of growth factors in squamous cell carcinoma and precan-cerous lesions of the lung. Clin. Cancer. Res., 8, 734-744.
26. Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E.P., de Herder, W.W., Goede, A., Caplin, M., Oberg, K., Reubi, J.C., Nilsson, O., Delle Fave, G., Ruszniewski, P., Ahlman, H. & Wiedenmann, B.; European Neuroendocrine Tumour Society.(2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society(ENETS). Neuroendocrinology, 80, 394-424.
27. Qiu, X., Wang, Z., Li, Y., Miao, Y., Ren, Y. & Luan, Y.(2012) Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett., 323, 161-170.
28. Reu, S., Neumann, J. & Kirchner, T.(2012) Gastrointestinal mixed adenoneuroendocrine carcinomas. An attempt at classifcation of mixed cancers. Pathologe, 33, 31-38.
29. Rindi, G., Kloppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W.W., Erikssson, B., Falchetti, A., Falconi, M., Komi-noth, P., Korner, M., Lopes, J.M., McNicol, A.M., Nilsson, O., Perren, A., Scarpa, A., Scoazec, J.Y., Wiedenmann, B. & all other Frascati Consensus Conference participants.(2006) TNM staging of foregut(neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch., 449, 395-401.
30. Sasaki, A., Kamiyama, T., Yokoo, H., Nakanishi, K., Kubota, K., Haga, H., Matsushita, M., Ozaki, M., Matsuno, Y. & Todo, S.(2010) Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep., 24, 537-546.
31. Soga, J. & Tazawa, K.(1971) Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer, 28, 990-998.
32. Thompson, M., Fleming, K.A., Evans, D.J., Fundele, R., Surani, M.A. & Wright, N.A.(1990) Gastric endocrine cells share a clonal origin with other gut cell lineages. Development, 110, 477-481.
33. Williams, E.D. & Sandler, M.(1963) The classification of carci-noid tumours. Lancet, 1, 238-239.
34. Xu, Y.H., Richert, N., Ito, S., Merlino, G.T. & Pastan, I.(1984) Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc. Natl. Acad. Sci. USA, 81, 7308-7312.
35. Yao, J.C., Phan, A., Hoff, P.M., Chen, H.X., Charnsangavej, C., Yeung, S.C., Hess, K., Ng, C., Abbruzzese, J.L. & Ajani, J.A.(2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol., 26, 1316-1323.
36. Ying, X., Wu, J., Meng, X., Zuo, Y., Xia, Q., Chen, J., Feng, Y., Liu, R., Li, L. & Huang, W.(2013) AC133 expression associated with poor prognosis in stage II colorectal cancer. Med. Oncol., 30, 356.
37. Zhang, S.S., Han, Z.P., Jing, Y.Y., Tao, S.F., Li, T.J., Wang, H., Wang, Y., Li, R., Yang, Y., Zhao, X., Xu, X.D., Yu, E.D., Rui, Y.C., Liu, H.J., Zhang, L. & Wei, L.X.(2012) CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med., 10, 85.